RxDoctor Payments Data

Rakesh Marwaha, MD

Internal Medicine · Naperville, ILNPI 1164539094

Payments from drug & device makers

$16,471in general payments, 2019–2025

Across 1,044 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Nestle Healthcare Nutrition Inc.$979
  • GSK$930
  • Amgen$924
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,32999%
  • Education$1421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca94$1,756
AbbVie(2 entities)104$1,359
Johnson & Johnson(2 entities)71$1,174
Nestle Healthcare Nutrition Inc.107$979
GSK64$930
Amgen(2 entities)55$924
Lilly USA, LLC59$897
Novo Nordisk62$844
Pfizer42$831
Corcept Therapeutics36$662
Xeris Pharmaceuticals, Inc.32$624
Boehringer Ingelheim33$584
Aimmune Therapeutics, Inc.35$332
Novartis18$298
Kowa Pharmaceuticals America, Inc.19$261
Otsuka America Pharmaceutical, Inc.11$258
Merck15$227
Bayer9$207
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$182
Orexo US, Inc.10$171
Sanofi Pasteur Inc.7$153
Astellas Pharma US Inc7$147
Teva Pharmaceuticals USA, Inc.8$121
Phathom Pharmaceuticals, Inc.9$120
Recordati_rare_diseases_inc.5$120
Sanofi-aventis U.S. LLC6$100
Indivior Inc.4$99
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$96
Eisai Inc.5$95
Insulet Corporation3$94
Supernus Pharmaceuticals, Inc.6$87
Hikma Pharmaceuticals USA5$86
Abbott4$83
Exact Sciences4$83
E.r. Squibb & Sons, L.L.C.5$80
Jazz Pharmaceuticals Inc.4$78
Adlon Therapeutics L.p.5$77
Dexcom, Inc.5$77
Ascensia Diabetes Care US Inc.3$76
Optos, Inc.3$68
Arbor Pharmaceuticals, Inc.4$63
Otsuka Pharmaceutical Development & Commercialization, Inc.3$61
Shield Therapeutics Inc3$58
Boston Scientific3$55
Seqirus USA Inc3$54
Genentech USA, Inc.3$46
USWM, LLC2$42
Takeda Pharmaceuticals U.S.A., Inc.2$39
Esperion Therapeutics, Inc.2$36
Masimo Corporation1$35
Si-bone, Inc.1$33
Actelion Pharmaceuticals US, Inc.1$33
Sanofi1$31
Mylan Specialty L.p.2$26
Medtronic(2 entities)2$25
Smith+Nephew1$25
Ironwood Pharmaceuticals, Inc1$24
Inspire Medical Systems, Inc.1$23
Tonix Medicines, Inc.1$23
Edwards Lifesciences1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,471 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$444,450
Medicare patients
380
Services billed
21,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide246$401,049
JardianceEmpagliflozin226$281,066
FarxigaDapagliflozin Propanediol73$98,273
EliquisApixaban74$85,890
XareltoRivaroxaban75$83,204
ZenpepLipase/Protease/Amylase45$70,455
LinzessLinaclotide51$50,004
TradjentaLinagliptin36$37,861
JanuviaSitagliptin Phosphate22$31,301
MounjaroTirzepatide27$31,156
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$28,062
VascepaIcosapent Ethyl39$26,784
AbrysvoRsv Vacc, Pref A And Pref B/Pf73$23,366
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$20,236
JanumetSitagliptin Phos/Metformin Hcl17$19,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$844$411,167257 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$584$339,550286 claims
PfizerEliquis, Abrysvo$831$109,256147 claims
AstraZenecaFarxiga$1,756$98,27373 claims
Johnson & JohnsonXarelto, Invokana$1,174$89,38188 claims
Aimmune Therapeutics, Inc.Zenpep$332$70,45545 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$930$56,667123 claims
MerckJanuvia, Janumet$227$51,18439 claims
AbbVieLinzess$1,359$50,00451 claims
Lilly USA, LLCMounjaro, Trulicity$897$49,20041 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine$86$27,574116 claims
Indivior Inc.Suboxone$99$15,30717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →